MEDNAX (NYSE:MD) Receives Daily Coverage Optimism Score of 0.11

News articles about MEDNAX (NYSE:MD) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. MEDNAX earned a news impact score of 0.11 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.1113938417511 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the media headlines that may have impacted Accern Sentiment’s scoring:

MEDNAX (NYSE MD) traded up $0.05 during midday trading on Monday, hitting $54.22. 446,400 shares of the company were exchanged, compared to its average volume of 878,111. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.37 and a quick ratio of 1.37. MEDNAX has a twelve month low of $40.56 and a twelve month high of $72.13. The company has a market cap of $5,077.99, a P/E ratio of 19.16, a P/E/G ratio of 1.63 and a beta of 0.39.

MEDNAX (NYSE:MD) last released its earnings results on Wednesday, November 1st. The company reported $0.87 EPS for the quarter, hitting analysts’ consensus estimates of $0.87. The business had revenue of $868.95 million for the quarter, compared to the consensus estimate of $864.78 million. MEDNAX had a net margin of 7.76% and a return on equity of 10.80%. The business’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.09 EPS. analysts forecast that MEDNAX will post 3.1 EPS for the current year.

Several research analysts have recently commented on MD shares. Piper Jaffray Companies started coverage on shares of MEDNAX in a report on Wednesday, December 13th. They issued an “overweight” rating and a $58.00 price target for the company. SunTrust Banks set a $55.00 price objective on shares of MEDNAX and gave the company a “hold” rating in a research report on Thursday, December 21st. BMO Capital Markets started coverage on shares of MEDNAX in a research report on Monday, October 16th. They issued a “market perform” rating and a $46.00 price objective on the stock. Zacks Investment Research upgraded shares of MEDNAX from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, KeyCorp set a $51.00 price objective on shares of MEDNAX and gave the company a “buy” rating in a research report on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the company. MEDNAX has an average rating of “Hold” and an average price target of $53.82.

In other news, insider John C. Pepia sold 3,000 shares of MEDNAX stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total value of $154,740.00. Following the transaction, the insider now directly owns 35,569 shares of the company’s stock, valued at $1,834,649.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Cesar L. Alvarez sold 10,668 shares of the business’s stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $42.59, for a total transaction of $454,350.12. Following the transaction, the director now directly owns 44,215 shares in the company, valued at $1,883,116.85. The disclosure for this sale can be found here. Company insiders own 2.40% of the company’s stock.

WARNING: “MEDNAX (NYSE:MD) Receives Daily Coverage Optimism Score of 0.11” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at

MEDNAX Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Insider Buying and Selling by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with's FREE daily email newsletter.

Leave a Reply